Literature DB >> 11514163

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.

E Pinard1, A Alanine, A Bourson, B Büttelmann, R Gill, M Heitz, G Jaeschke, V Mutel, G Trube, R Wyler.   

Abstract

Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at alpha(1) adrenergic receptors were developed.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11514163     DOI： 10.1016/s0960-894x(01)00392-4

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  2 in total

1.  Blockade of NMDA GluN2B receptors selectively impairs behavioral flexibility but not initial discrimination learning.

Authors:  Gemma L Dalton; Liya M Ma; Anthony G Phillips; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2011-03-08       Impact factor: 4.530

2.  An MCASE approach to the search of a cure for Parkinson's Disease.

Authors:  Gilles Klopman; Aleksandr Sedykh
Journal:  BMC Pharmacol       Date:  2002-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.